Clinical Trials Logo

Clinical Trial Summary

This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy. Patients in which anticoagulante therapy is mantained will be compared to those in which it is interrupted, in terms of stroke or systemic embolism and haemorrhagic transformation.


Clinical Trial Description

Observational, prospective, multicenter, cohort study in patients with recent cardioembolic stroke (<24 hours) and previous oral or parenteral anticoagulant therapy (last dose recieved <24hours) . Patients in which anticoagulante therapy is mantained will be compared to those in which it is interrupted. The decision to mantain or interrumpt the anticoagulant therapy is made by the treating physician as hospital protocol. Stroke recurrence, haemorrhagic transformation at 90 days are evalauted and also complication during the hospitalization and functional outcome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05486351
Study type Observational
Source Instituto de Investigación Hospital Universitario La Paz
Contact Ricardo Rigual Bobillo, MD
Phone 917277444
Email [email protected]
Status Recruiting
Phase
Start date March 5, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05361889 - ReAl-life multIceNter Outcomes Registry for Better antithrOmbotic Strategies in Patients With AF (RAINBOW-AF)
Completed NCT03143569 - Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial N/A
Completed NCT04623177 - Thromboprophylaxis for Patients in ICU With COVID-19
Withdrawn NCT01541098 - A Clinical Study of Lyophilized Plasma in Patients on Warfarin Phase 2
Active, not recruiting NCT04351438 - Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation
Recruiting NCT05181774 - Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics
Completed NCT03182829 - In Vitro Diagnostic Test for DOAC in Urine